Articles from Landmark Medicines

Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation
Proprietary intranasal delivery technology being developed initially for GLP-1 receptor agonists
By Landmark Medicines · Via GlobeNewswire · September 29, 2026